These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27814726)

  • 1. Absolute volume of the rectum and AUC from rectal DVH between 25Gy and 50Gy predict acute gastrointestinal toxicity with IG-IMRT in prostate cancer.
    Mirjolet C; Walker PM; Gauthier M; Dalban C; Naudy S; Mazoyer F; Martin E; Maingon P; Créhange G
    Radiat Oncol; 2016 Nov; 11(1):145. PubMed ID: 27814726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
    Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
    Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
    Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
    Vargas C; Martinez A; Kestin LL; Yan D; Grills I; Brabbins DS; Lockman DM; Liang J; Gustafson GS; Chen PY; Vicini FA; Wong JW
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1297-308. PubMed ID: 16029785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415.
    Thor M; Deasy JO; Paulus R; Robert Lee W; Amin MB; Bruner DW; Low DA; Shah AB; Malone SC; Michalski JM; Dayes IS; Seaward SA; Gore EM; Albert M; Pisansky TM; Faria SL; Chen Y; Koontz BF; Swanson GP; Pugh SL; Sandler HM
    Radiother Oncol; 2019 Jun; 135():19-24. PubMed ID: 31015166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
    Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.
    Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical analysis of dose-volume profiles and its implication for radiation therapy planning in prostate carcinoma.
    Vanasek J; Odrazka K; Dolezel M; Kolarova I; Jarkovsky J; Pavlik T; Hlavka A; Dusek L
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):769-76. PubMed ID: 23628133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
    Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer.
    Peeters ST; Hoogeman MS; Heemsbergen WD; Slot A; Tabak H; Koper PC; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1142-52. PubMed ID: 15939547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute toxicity in definitive versus postprostatectomy image-guided radiotherapy for prostate cancer.
    Cheng JC; Schultheiss TE; Nguyen KH; Wong JY
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):351-7. PubMed ID: 18164841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients.
    De Meerleer G; Vakaet L; Meersschout S; Villeirs G; Verbaeys A; Oosterlinck W; De Neve W
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):777-87. PubMed ID: 15465194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.
    Fang P; Mick R; Deville C; Both S; Bekelman JE; Christodouleas JP; Guzzo TJ; Tochner Z; Hahn SM; Vapiwala N
    Cancer; 2015 Apr; 121(7):1118-27. PubMed ID: 25423899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of changing rectal dose volume parameters over time on late rectal and urinary toxicity after high-dose intensity-modulated radiotherapy for prostate cancer: A 10-years single centre experience.
    Fonteyne V; Sadeghi S; Ost P; Vanpachtenbeke F; Vuye P; Lumen N; De Meerleer G
    Acta Oncol; 2015 Jun; 54(6):854-61. PubMed ID: 25387271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Who will benefit most from hydrogel rectum spacer implantation in prostate cancer radiotherapy? A model-based approach for patient selection.
    Vanneste BG; Hoffmann AL; van Lin EN; Van De Voorde L; Pinkawa M; Lambin P
    Radiother Oncol; 2016 Oct; 121(1):118-123. PubMed ID: 27647458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nomogram to predict rectal toxicity following prostate cancer radiotherapy.
    Delobel JB; Gnep K; Ospina JD; Beckendorf V; Chira C; Zhu J; Bossi A; Messai T; Acosta O; Castelli J; de Crevoisier R
    PLoS One; 2017; 12(6):e0179845. PubMed ID: 28640871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-escalated simultaneous integrated-boost treatment of prostate cancer patients via helical tomotherapy.
    Geier M; Astner ST; Duma MN; Jacob V; Nieder C; Putzhammer J; Winkler C; Molls M; Geinitz H
    Strahlenther Onkol; 2012 May; 188(5):410-6. PubMed ID: 22367410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of gastrointestinal toxicity after external beam radiotherapy for localized prostate cancer.
    D'Avino V; Palma G; Liuzzi R; Conson M; Doria F; Salvatore M; Pacelli R; Cella L
    Radiat Oncol; 2015 Apr; 10():80. PubMed ID: 25890376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rectal wall sparing by dosimetric effect of rectal balloon used during intensity-modulated radiation therapy (IMRT) for prostate cancer.
    Teh BS; Dong L; McGary JE; Mai WY; Grant W; Butler EB
    Med Dosim; 2005; 30(1):25-30. PubMed ID: 15749008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.